xmab27564
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 19, 2021 (NCT04857866)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-2 receptor alpha chainINHIBITOR
IL2RA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06005792 | Phase 1 | Oct 10, 2022 | Xencor |
| NCT04857866 | Phase 1 | Apr 19, 2021 | ICON, Xencor |
Showing 2 of 2 trials
Page 1 / 1